Medical Education Grant

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) - BI Cares Foundation


Grant amount: Unspecified amount

Deadline: Rolling

Applicant type: Organizations

Funding uses: Conference, Education / Outreach

Location of project: United States

Location of residency: United States

View website    Save Need help writing this grant?

Overview:

Boehringer Ingelheim is proud to provide Medical Education Grant support for specific independent educational activities for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats. 

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI. 

BIPI considers funding of activities both independently and through its alliance arrangement with Lilly USA, LLC (Lilly) in a variety of areas including:

BIPI Areas of Strategic Focus

Cardiovascular

Stroke Prevention in Atrial Fibrillation (Limited Funding Available)

  • Enable clinicians to make informed treatment recommendations for cardioembolic stroke risk reduction in individual NVAF patients based upon current guidelines, emerging data, patient co-morbidities, lifestyle, and social factors
  • Educate clinicians about the diagnosis and treatment of embolic stroke of unknown source (ESUS)
  • Increase clinicians’ knowledge of the management of bleeding and reversal options in patients on oral anticoagulants, or patients at risk of bleeding who are taking oral anticoagulants

Oncology

Mesothelioma – 2018 Medical Education Objectives

  • Expand clinician’s understanding of the incidence, diagnosis, histology and current treatment algorithms for mesothelioma
  • Identify the unmet medical need in prolonging progression-free survival (PFS) and overall survival (OS) for patients with mesothelioma
  • Discuss the role of angiogenesis and related growth factor signaling pathways in the pathology of pleural mesothelioma
  • Understand anti-angiogenic agents and emerging data with oral angiokinase inhibitors in pleural mesothelioma

Non-Small Cell Lung Cancer – 2018 Medical Education Objectives (Limited Funding Available)

  • Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations (e.g. different histologies, different sub-types) to optimize therapeutic strategies.
  • Increase clinicians’ understanding of treating patients with EGFR positive NSCLC in the light of resistance mechanism after 1st line treatment with anti-EGFR agents.
  • Review the management of adverse events associated with the use of oral anti-EGFR agents.
  • Increase clinicians’ understanding of biology, incidence and treatment options for patients with NSCLC and uncommon EGFR mutations

Respiratory

Asthma (Limited Funding Available)

  • Improve HCPs’ understanding and approach to the recognition, diagnosis, and optimal management of patients (pediatric, adolescent and adult) with asthma, including those with difficult to control asthma and/or those with specific phenotypes, in accordance with accepted standards. 
  • Improve patient/caregiver awareness and knowledge of asthma diagnosis and treatment.
  • Educate HCPs, patients, and caregivers on the proper use of different inhalers and implementing self-management strategies. 

Chronic Obstructive Pulmonary Disease (COPD)

  • Improve HCPs’ understanding of the current treatment recommendations and scientific evidence supporting individualized treatment in COPD care and the appropriate use of dual bronchodilation and ICS for airflow obstruction, symptom management and reduction in exacerbations.
  • Enhance HCPs' awareness and knowledge of multidisciplinary approaches to improve transition of care in COPD and reduce health care resource utilization.
  • Improve patient/caregiver awareness and knowledge of COPD diagnosis and treatment.
  • Educate HCPs, patients, and caregivers on the proper use of different inhalers and implementing self-management strategies.

Interstitial Lung Disease (ILD) 

  • Disease course, diagnosis and risk assessment: Increase clinicians’ understanding of disease prevalence, morbidity and mortality, burden of illness, and signs and symptoms of ILD (IPF, Connective Tissue Disease (CTD) related ILD). Additionally improve clinician’s knowledge of recommended diagnostic testing methods and interpretation (e.g. HRCT, surgical biopsy, serologic testing) and the importance of routine, comprehensive multidisciplinary assessments in patients with CTD-ILD.
  • Earlier identification and differentiation of ILDs: Raise the index of awareness of ILD among HCPs to encourage earlier referral of appropriate patients with ILD (IPF and Connective Tissue Disease related ILD) to ILD centers.
  • Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding IPF clinical management, including developments in clinical research and treatment guidelines.
  • IPF risk factors and co-morbidities: Increase understanding among pulmonologists regarding management of the possible IPF risk factors (such as pharmacogenetics, pharmacogenomics) and co-morbidities for IPF (such as GERD), as well as the importance of managing other co-morbidities.
  • HCP communication with patients: Improve clinicians understanding of how to effectively communicate and educate ILD patients about their disease.

Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

  • Disease course, diagnosis and risk assessment: Increase clinicians’ understanding of disease pathophysiology, prevalence, morbidity and mortality and signs and symptom of SSc-ILD. Additionally improve clinician’s knowledge about the need to evaluate and monitor lung involvement in patients with SSc (e.g. HRCT scan, PFTs).
  • Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding SSc-ILD clinical management, including developments in clinical research and treatment guidelines.
  • HCP communication with patients: Improve clinicians understanding of how to effectively communicate and educate SSc-ILD patients about their disease.

Interstitial Lung Diseases (ILDs) with Progressive Lung Disease Phenotype

  • Description of ILDs with Progressive Lung Disease Phenotype: Improve clinician’s knowledge about the diseases most commonly associated with ILDs with Progressive Lung Disease Phenotype (i.e. Rheumatoid Arthritis, Chronic Hypersensitivity Pneumonitis, Unclassified ILD) and the need to monitor lung involvement in patients with these diseases.
  • Disease course, diagnosis and assessment: Increase clinicians’ understanding of disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of ILDs with Progressive Lung Disease Phenotype.
  • Clinical management: Improve clinicians’ knowledge regarding ILDs with Progressive Lung Disease Phenotype clinical management, including developments in clinical research and treatment guidelines.

You can learn more about this opportunity by visiting the funder's website.

Eligibility:

  • A medical education grant must be designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.
  • Grant applications must be submitted no less than 60 days prior to the program start date.


About this funder:

Loading...
View past grantees & full 990 summary